Skip to main content
. 2014 Jan 13;123(12):1826–1832. doi: 10.1182/blood-2013-11-538835

Figure 2.

Figure 2

PFS and OS. (A) PFS in the intent-to-treat population. (B) OS in the intent-to-treat population. (C) PFS in patients with disease refractory to LEN. (D) OS in patients with disease refractory to LEN. (E) PFS in patients with disease refractory to both LEN and BORT. (F) OS in patients with disease refractory to both LEN and BORT.